Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ATOS 
Atossa Genetics Inc (ATOS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: ATOS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -15.49% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 84.09M USD | Price to earnings Ratio - | 1Y Target Price 6 |
Price to earnings Ratio - | 1Y Target Price 6 | ||
Volume (30-day avg) 527591 | Beta 1.2 | 52 Weeks Range 0.65 - 2.31 | Updated Date 04/1/2025 |
52 Weeks Range 0.65 - 2.31 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.2 |
Earnings Date
Report Date 2025-03-31 | When Before Market | Estimate -0.0633 | Actual -0.05 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -19.99% | Return on Equity (TTM) -31.39% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 13005673 | Price to Sales(TTM) - |
Enterprise Value 13005673 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 2.01 | Shares Outstanding 129170000 | Shares Floating 129086043 |
Shares Outstanding 129170000 | Shares Floating 129086043 | ||
Percent Insiders 0.07 | Percent Institutions 27.81 |
Analyst Ratings
Rating 4.33 | Target Price 6 | Buy 2 | Strong Buy 1 |
Buy 2 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Atossa Genetics Inc
Company Overview
History and Background
Atossa Therapeutics, Inc. (formerly Atossa Genetics, Inc.) was founded in 2009. It is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a focus on breast cancer and other cancers.
Core Business Areas
- Segment Name 1: Drug Development: Focuses on developing proprietary therapeutics and diagnostics for breast cancer and other cancers, including Endoxifen, a potential treatment for breast cancer prevention and treatment.
Leadership and Structure
Atossa Therapeutics is led by a management team with experience in the pharmaceutical and biotechnology industries. Steven C. Quay, M.D., Ph.D., is the President and CEO. The company has a Board of Directors overseeing its strategic direction.
Top Products and Market Share
Key Offerings
- Product Name 1: Endoxifen: A proprietary oral formulation of a selective estrogen receptor modulator (SERM) being developed for breast cancer prevention and treatment. Market share data is currently unavailable due to its development stage. Competitors include established SERMs like Tamoxifen and aromatase inhibitors.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive. The breast cancer treatment market is large and growing, driven by increasing incidence rates and advances in treatment options.
Positioning
Atossa Therapeutics is positioned as an innovator in breast cancer therapeutics, focusing on developing novel drugs and diagnostics. Their competitive advantage lies in their proprietary Endoxifen formulation and targeted approach.
Total Addressable Market (TAM)
The global breast cancer therapeutics market is estimated to be worth billions of dollars. Atossa is targeting a portion of this TAM with its Endoxifen program. Its TAM also includes breast cancer prevention which further increases this TAM.
Upturn SWOT Analysis
Strengths
- Proprietary Endoxifen formulation
- Focus on unmet needs in breast cancer
- Experienced management team
- Strong IP Portfolio
Weaknesses
- Limited financial resources
- Reliance on clinical trial success
- Small market capitalization
- Single Lead Product
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new cancer indications
- FDA Fast Track Designation
Threats
- Competition from established breast cancer therapies
- Regulatory hurdles
- Clinical trial failures
- Market acceptance of novel therapies
Competitors and Market Share
Key Competitors
- AZN
- PFE
- MRK
- GILD
Competitive Landscape
Atossa faces stiff competition from large pharmaceutical companies with established breast cancer therapies. Its advantage lies in novel approach with its endoxifen.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by preclinical and clinical development of its Endoxifen program, along with related financings.
Future Projections: Future growth depends on successful clinical trials and regulatory approvals. Analyst estimates vary significantly based on these uncertainties.
Recent Initiatives: Recent initiatives include advancing Endoxifen through clinical trials, seeking strategic partnerships, and exploring new indications for its technology.
Summary
Atossa Therapeutics is a clinical-stage biopharmaceutical company focused on breast cancer therapeutics. Its strengths lie in its proprietary Endoxifen formulation, but it faces risks associated with clinical trials, regulatory hurdles, and competition from larger companies. Success depends on positive trial results and securing partnerships to further develop its pipeline. The company's financial stability and market capitalization are also crucial factors to consider.
Similar Companies
ARRY
Array Technologies Inc
ARRY
Array Technologies Inc
KPTI
Karyopharm Therapeutics Inc
KPTI
Karyopharm Therapeutics Inc
NKTR
Nektar Therapeutics
NKTR
Nektar Therapeutics
Sources and Disclaimers
Data Sources:
- Company filings
- Third-party financial data providers
- Industry reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and assumptions, which are subject to change. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Atossa Genetics Inc
Exchange NASDAQ | Headquaters Seattle, WA, United States | ||
IPO Launch date 2012-11-08 | Chairman, CEO & President Dr. Steven C. Quay FCAP, M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 15 | |
Full time employees 15 | |||
Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.